A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

Trial Profile

A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Aprepitant (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 02 Sep 2015 According to Merck & Co. media release, supplemental NDA for aprepitant (EMEND) in combination with other antiemetics has been approved by the US FDA for use in patients 12 years of age and older and patients less than 12 years who weigh at least 30 kg for the prevention of chemotherapy induced nausea and vomiting based partly on data from this trial.
    • 22 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 30 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top